Evidence map›Paper›PMID 39931803›Full record

ArticleAngewandte Chemie (International ed. in English)2025

Binding-Site Purification of Actives (B-SPA) Enables Efficient Large-Scale Progression of Fragment Hits by Combining Multi-Step Array Synthesis With HT Crystallography.

Harold Grosjean, Anthony Aimon, Storm Hassell-Hart, Warren Thompson, Lizbé Koekemoer, James Bennett, Anthony Bradley, Cameron Anderson, Conor Wild, William J Bradshaw and 6 more

Abstract read
In one paragraph

Article in Angewandte Chemie (International ed. in English), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. How many crystal structures do you need to trust your docking results?bioRxiv : the preprint server for biology · 2025
    Article
  7. Article
  8. Article
  9. Fragment-based drug discovery: A graphical review.Current research in pharmacology and drug discovery · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Harold GrosjeanDiamond Light Source Ltd, Harwell Science and Innovation Campus, OX11 0QX, Didcot, UK.ORCID https://orcid.org/0000-0002-1095-5578
Anthony AimonDiamond Light Source Ltd, Harwell Science and Innovation Campus, OX11 0QX, Didcot, UK.ORCID https://orcid.org/0000-0002-9135-129X
Storm Hassell-HartDepartment of Chemistry, School of Life Sciences, University of Sussex, Falmer, BN1 9QJ, UK.ORCID https://orcid.org/0000-0001-6511-6037
Warren ThompsonDiamond Light Source Ltd, Harwell Science and Innovation Campus, OX11 0QX, Didcot, UK.ORCID https://orcid.org/0000-0003-1474-7810
Lizbé KoekemoerCentre for Medicines Discovery, University of Oxford, Old Road Campus, Roosevelt Drive, OX3 7DQ, Headington, UK.ORCID https://orcid.org/0000-0001-9226-9127
James BennettCentre for Medicines Discovery, University of Oxford, Old Road Campus, Roosevelt Drive, OX3 7DQ, Headington, UK.ORCID https://orcid.org/0000-0003-1396-8400
Anthony BradleyStructural Genomics Consortium, University of Oxford, Old Road Campus, Roosevelt Drive, OX3 7DQ, Headington, UK.ORCID https://orcid.org/0000-0002-0881-3490
Cameron AndersonStructural Bioinformatics and Computational Biochemistry, Departement of Biochemistry, University of Oxford, South Parks Road, OX1 3QU, Oxford, UK.ORCID https://orcid.org/0000-0001-9883-7105
Conor WildDiamond Light Source Ltd, Harwell Science and Innovation Campus, OX11 0QX, Didcot, UK.
William J BradshawCentre for Medicines Discovery, University of Oxford, Old Road Campus, Roosevelt Drive, OX3 7DQ, Headington, UK.ORCID https://orcid.org/0000-0002-7985-9752
Edward A FitzGeraldCreoptix AG, Zugerstrasse 76, 8820, Wädenswil, Switzerland.ORCID https://orcid.org/0000-0002-0603-1241
Tobias KrojerStructural Genomics Consortium, University of Oxford, Old Road Campus, Roosevelt Drive, OX3 7DQ, Headington, UK.ORCID https://orcid.org/0000-0003-0661-0814
Oleg FedorovStructural Genomics Consortium, University of Oxford, Old Road Campus, Roosevelt Drive, OX3 7DQ, Headington, UK.ORCID https://orcid.org/0000-0001-9004-1815
Philip C BigginStructural Bioinformatics and Computational Biochemistry, Departement of Biochemistry, University of Oxford, South Parks Road, OX1 3QU, Oxford, UK.ORCID https://orcid.org/0000-0001-5100-8836
John SpencerDepartment of Chemistry, School of Life Sciences, University of Sussex, Falmer, BN1 9QJ, UK.ORCID https://orcid.org/0000-0001-5231-8836
Frank von DelftDiamond Light Source Ltd, Harwell Science and Innovation Campus, OX11 0QX, Didcot, UK.ORCID https://orcid.org/0000-0003-0378-0017

Funding

Engineering and Physical Sciences Research Council EP/P026990/1
6 · The paper itself

Abstract

Fragment approaches are long-established in target-based ligand discovery, yet their full transformative potential lies dormant because progressing the initial weakly binding hits to potency remains a formidable challenge. The only credible progression paradigm involves multiple cycles of costly conventional design-make-test-analyse medicinal chemistry. We propose an alternative approach to fragment elaboration, namely performing large numbers of parallel and diverse automated multiple step reactions, and evaluating the binding of the crude reaction products by high-throughput protein X-ray crystallography. We show it is effective and low-cost to perform, in parallel, large numbers of non-uniform multi-step reactions, because, even without compound purification, crystallography provides a high-quality readout of binding. This can detect low-level binding of weakly active compounds, which the target binding site extracts directly from crude reaction mixtures. In this proof-of-concept study, we have expanded a fragment hit, from a crystal-based screen of the second bromodomain of pleckstrin homology domain-interacting protein (PHIP(2)), using array synthesis on low-cost robotics. We were able to implement 6 independent multi-step reaction routes of up to 5 steps, attempting the synthesis of 1876 diverse expansions, designs entirely driven by synthetic tractability. The expected product was present in 1108 (59%) crude reaction mixtures, detected by liquid chromatography mass spectrometry (LCMS). 22 individual products were resolved in the crystal structures of crude reaction mixtures added to crystals, providing an initial structure activity relationship map. 19 of these showed binding pose stability, while, through binding instability in the remaining 3 products, we could resolve a stereochemical preference for mixtures containing racemic compounds. One compound showed biochemical potency (IC

Indexed as

Binding SitesCrystallography, X-RayLigandsLigandsarray synthesisautomated synthesisbromodomain inhibitorFragment-based drug discoveryhigh-throughput x-ray crystallography

Identifiers

PMID39931803
PMCPMC12001203

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.